Related Experiment Videos
Successful management with interferon alpha-2a after prednisone therapy failure in an infant with a giant cavernous
M A Castello1, G Ragni, A Antimi
1Department of Pediatrics, University La Sapienza, Rome, Italy.
Insights
Interferon alpha-2a effectively treated a neonate's giant cavernous hemangioma, resolving severe thrombocytopenia and coagulopathy. This treatment led to rapid improvement and eventual disappearance of the hemangioma.
Area of Science:
- Pediatric Oncology
- Hematology
- Vascular Anomalies
Background:
- Giant cavernous hemangiomas can cause life-threatening complications in neonates.
- Severe thrombocytopenia and consumptive coagulopathy are significant risks associated with these vascular tumors.
Observation:
- A neonate presented with a large left arm cavernous hemangioma, accompanied by severe thrombocytopenia and coagulopathy.
- Initial treatments including prednisone, platelet transfusions, and clotting factor replacement were ineffective in controlling bleeding.
Findings:
- Daily subcutaneous interferon alpha-2a infusions were initiated for the neonate.
- Treatment with interferon alpha-2a led to rapid improvement in coagulopathy and a significant reduction in transfusion needs.
- The hemangioma showed progressive regression, disappearing completely within four months.
Implications:
- Interferon alpha-2a represents a promising therapeutic option for neonates with complex hemangiomas and associated coagulopathies.
- This case highlights the potential of targeted therapy in managing severe vascular anomalies and hematologic complications in newborns.
- Further research into interferon-based therapies could offer new avenues for treating challenging pediatric vascular tumors.
Abstract:
A giant cavernous hemangioma of the left arm with severe thrombocytopenia and consumptive coagulopathy was observed in a neonate. Initial treatment with prednisone, platelet transfusions, and clotting replacement failed to control the bleedings. The child was then treated with daily subcutaneous infusions of interferon alpha-2a. Coagulopathy rapidly improved and transfusions were drastically reduced. The hemangioma regressed progressively and disappeared after 4 months of treatment.